抗毒素の市場規模、シェア、成長分析：抗毒素タイプ別、生物の種類別、作用機序別、エンドユーザー別、地域別 - 産業予測 2025～2032年

抗毒素市場規模は2023年に21億米ドルと評価され、予測期間（2025～2032年）のCAGRは8.1%で、2024年の22億7,000万米ドルから2032年には42億3,000万米ドルに成長する見通しです。

世界の抗毒素市場は、ヘビ咬傷の発生率の上昇と効果的な治療オプションに対する意識の高まりにより、大きな成長を遂げています。ヘビ咬傷は、特にサハラ以南のアフリカ、南アジア、東南アジアなど、毒を持つ種が蔓延している地域において、公衆衛生上の大きな懸念であり続けています。WHOによると、ヘビ咬傷は毎年数万人の死者を出しており、生存者の多くが長期的な障害に苦しんでいます。政府、NGO、ヘルスケアプロバイダーは、抗毒素へのアクセスを積極的に改善し、生産と流通を促進しています。バイオテクノロジーの進歩により、より安全で効果的な製剤が開発され、治療成績が向上しています。しかし、高コスト、標準化の欠如、複雑な製造工程といった課題が、特に経済的な余裕が重要な課題となっている低所得地域における市場拡大の妨げとなっています。

目次

イントロダクション

• 調査の目的
• 調査範囲
• 定義

調査手法

• 情報調達
• 二次データと一次データの方法
• 市場規模予測
• 市場の前提条件と制限

エグゼクティブサマリー

• 世界市場の見通し
• 供給と需要の動向分析
• セグメント別機会分析

市場力学と見通し

• 市場概要
• 市場規模
• 市場力学
  • 促進要因と機会
  • 抑制要因と課題
• ポーターの分析

主な市場の考察

• 重要成功要因
• 競合の程度
• 主な投資機会
• 市場エコシステム
• 市場の魅力指数（2024年）
• PESTEL分析
• マクロ経済指標
• バリューチェーン分析
• 価格分析
• 規制情勢
• ケーススタディ
• 技術の進歩
• 貿易分析

抗毒素市場規模：抗毒素タイプ別

• 市場概要
• 多価
• 一価
• その他

抗毒素市場規模：生物の種類別

• 市場概要
• ヘビの抗毒素
• サソリの抗毒素
• クモの抗毒素
• その他

抗毒素市場規模：作用機序別

• 市場概要
• 細胞毒性
• 神経毒性
• 血液毒性
• 心臓毒性
• 筋毒性
• その他

抗毒素市場規模：エンドユーザー別

• 市場概要
• 病院・診療所
• 外来手術センター
• 調査機関
• その他

抗毒素市場規模

• 北米
  • 米国
  • カナダ
• 欧州
  • ドイツ
  • スペイン
  • フランス
  • 英国
  • イタリア
  • その他欧州地域
• アジア太平洋地域
  • 中国
  • インド
  • 日本
  • 韓国
  • その他アジア太平洋地域
• ラテンアメリカ
  • ブラジル
  • その他ラテンアメリカ地域
• 中東・アフリカ
  • GCC諸国
  • 南アフリカ
  • その他中東・アフリカ

競合情報

• 上位5社の比較
• 主要企業の市場ポジショニング（2024年）
• 主な市場企業が採用した戦略
• 市場の最近の動向
• 企業の市場シェア分析（2024年）
• 主要企業の企業プロファイル
  • 会社概要
  • 製品ポートフォリオ分析
  • セグメント別シェア分析
  • 収益の前年比比較（2022～2024年）

主要企業プロファイル

• BTG plc（United Kingdom）
• Laboratorios Silanes（Mexico）
• CSL Limited（Australia）
• Pfizer Inc.（United States）
• Merck & Co., Inc.（United States）
• Bharat Serums and Vaccines Limited（India）
• Haffkine Bio-Pharmaceutical Corporation Ltd（India）
• Boehringer Ingelheim International GmbH（Germany）
• Rare Disease Therapeutics Inc.（United States）
• South African Vaccine Producers（Pty）Ltd（South Africa）
• Instituto Butantan（Brazil）
• Instituto Clodomiro Picado（Costa Rica）
• Vins Bioproducts Limited（India）
• MicroPharm Limited（United Kingdom）
• Protherics PLC（United Kingdom）
• Inosan Biopharma（Spain）
• Sanofi Pasteur（France）
• Serum Institute of India Pvt. Ltd.（India）
• Bio-Pharmaceutical Corporation Ltd.（China）
• Thai Red Cross Society（Thailand）

結論と推奨事項

Anti-Venom Market size was valued at USD 2.1 billion in 2023 and is poised to grow from USD 2.27 billion in 2024 to USD 4.23 billion by 2032, growing at a CAGR of 8.1% during the forecast period (2025-2032).

The global anti-venom market is experiencing significant growth, driven by the rising incidence of snakebites and increasing awareness of effective treatment options. Snakebites remain a major public health concern, particularly in regions such as Sub-Saharan Africa, South Asia, and Southeast Asia, where venomous species are prevalent. According to WHO, snakebites cause tens of thousands of deaths annually, with many survivors suffering long-term disabilities. Governments, NGOs, and healthcare providers are actively improving access to anti-venom, boosting production and distribution. Advancements in biotechnology have led to safer and more effective formulations, enhancing treatment outcomes. However, challenges such as high costs, lack of standardization, and complex production processes continue to hinder market expansion, particularly in low-income regions where affordability remains a critical issue.

Top-down and bottom-up approaches were used to estimate and validate the size of the Anti-Venom Market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Anti-Venom Market Segments Analysis

Global Anti-Venom Market is segmented by Anti-venom Type, Species Type, Mode of Action, End User and region. Based on Anti-venom Type, the market is segmented into Polyvalent, Monovalent and Others. Based on Species Type, the market is segmented into Snake Antivenom, Scorpion Anti-venom, Spider Anti-venom and Others. Based on Mode of Action, the market is segmented into Cytotoxic, Neurotoxic, Haemotoxic, Cardiotoxic, Myotoxic and Others. Based on End User, the market is segmented into Hospitals & clinics, Ambulatory Surgical Centers, Research Institutes and Others. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Anti-Venom Market

Our analysis reveals that the growing incidence of snakebite cases globally is a crucial factor driving the expansion of the anti-venom market. Snakebites pose a severe public health challenge, particularly in regions with dense snake populations, such as parts of Asia, Africa, and Latin America. The World Health Organization (WHO) classifies snakebite envenomation as a neglected tropical disease, emphasizing the urgent need for effective treatments. Rising awareness, improved healthcare access, and government initiatives to provide life-saving anti-venom therapies are further propelling market growth. As snakebite cases continue to surge, the demand for reliable and affordable anti-venom solutions is expected to rise.

Restraints in the Anti-Venom Market

Our analysis reveals that inadequate healthcare infrastructure and logistical challenges in remote or rural areas significantly restrain the growth of the global anti-venom market. Limited access to medical facilities and a lack of proper cold chain storage for anti-venom distribution hinder its timely availability, increasing the risk of fatality and severe complications among snakebite victims. Additionally, transportation difficulties and insufficient trained healthcare personnel further exacerbate the issue, delaying critical treatment. These barriers contribute to uneven market penetration, limiting the adoption of anti-venom therapies in regions where snakebites are prevalent, ultimately affecting the overall market growth and accessibility of life-saving treatments.

Market Trends of the Anti-Venom Market

Our analysis reveals that increasing awareness and education campaigns are emerging as a key trend in the Global Anti-Venom Market. Governments, healthcare organizations, and non-profits are actively launching initiatives to educate healthcare professionals, communities, and individuals about snakebite prevention, early recognition, and appropriate treatment. These programs aim to reduce mortality and morbidity associated with venomous bites by improving response times and access to medical intervention. Additionally, digital platforms, workshops, and community outreach efforts are enhancing public knowledge and preparedness, ultimately driving demand for anti-venom products and supporting the market's growth through improved treatment accessibility and effectiveness.

Table of Contents

Introduction

• Objectives of the Study
• Scope of the Report
• Definitions

Research Methodology

• Information Procurement
• Secondary & Primary Data Methods
• Market Size Estimation
• Market Assumptions & Limitations

Executive Summary

• Global Market Outlook
• Supply & Demand Trend Analysis
• Segmental Opportunity Analysis

Market Dynamics & Outlook

• Market Overview
• Market Size
• Market Dynamics
  • Drivers & Opportunities
  • Restraints & Challenges
• Porters Analysis
  • Competitive rivalry
  • Threat of substitute
  • Bargaining power of buyers
  • Threat of new entrants
  • Bargaining power of suppliers

Key Market Insights

• Key Success Factors
• Degree of Competition
• Top Investment Pockets
• Market Ecosystem
• Market Attractiveness Index, 2024
• PESTEL Analysis
• Macro-Economic Indicators
• Value Chain Analysis
• Pricing Analysis
• Regulatory Landscape
• Case Studies
• Technological Advancement
• Trade Analysis

Global Anti-Venom Market Size by Anti-venom Type & CAGR (2025-2032)

• Market Overview
• Polyvalent
• Monovalent
• Others

Global Anti-Venom Market Size by Species Type & CAGR (2025-2032)

• Market Overview
• Snake Antivenom
• Scorpion Anti-venom
• Spider Anti-venom
• Others

Global Anti-Venom Market Size by Mode of Action & CAGR (2025-2032)

• Market Overview
• Cytotoxic
• Neurotoxic
• Haemotoxic
• Cardiotoxic
• Myotoxic
• Others

Global Anti-Venom Market Size by End User & CAGR (2025-2032)

• Market Overview
• Hospitals & clinics
• Ambulatory Surgical Centers
• Research Institutes
• Others

Global Anti-Venom Market Size & CAGR (2025-2032)

• North America (Anti-venom Type, Species Type, Mode of Action, End User)
  • US
  • Canada
• Europe (Anti-venom Type, Species Type, Mode of Action, End User)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (Anti-venom Type, Species Type, Mode of Action, End User)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (Anti-venom Type, Species Type, Mode of Action, End User)
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Anti-venom Type, Species Type, Mode of Action, End User)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2024
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2024
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2022-2024)

Key Company Profiles

• BTG plc (United Kingdom)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Laboratorios Silanes (Mexico)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• CSL Limited (Australia)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Pfizer Inc. (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Merck & Co., Inc. (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bharat Serums and Vaccines Limited (India)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Haffkine Bio-Pharmaceutical Corporation Ltd (India)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Boehringer Ingelheim International GmbH (Germany)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Rare Disease Therapeutics Inc. (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• South African Vaccine Producers (Pty) Ltd (South Africa)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Instituto Butantan (Brazil)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Instituto Clodomiro Picado (Costa Rica)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Vins Bioproducts Limited (India)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• MicroPharm Limited (United Kingdom)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Protherics PLC (United Kingdom)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Inosan Biopharma (Spain)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sanofi Pasteur (France)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Serum Institute of India Pvt. Ltd. (India)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bio-Pharmaceutical Corporation Ltd. (China)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Thai Red Cross Society (Thailand)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations